Monalizumab Biosimilar – Anti-KLRC1, NKG2A, CD159a, CD94 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade |
|---|---|
| Source | CAS 1228763-95-8 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Monalizumab,IPH-2201,NN-8765,NNC-0141-0000-0100,NNC-141-01000,anti-NKG2A,humZ270,KLRC1, NKG2A, CD159a, CD94,anti-KLRC1, NKG2A, CD159a, CD94 |
| Reference | PX-TA1392 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG4-kappa |
| Clonality | Monoclonal Antibody |
General information on Anti-KLRC1/NKG2A/CD159a/CD94[Homo sapiens] (Monalizumab) Monoclonal Antibody
Monalizumab has been investigated for the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
SDS-PAGE for Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb
Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Related products
Antigen
Human CD159a-KLRC1 recombinant protein
PX-P6098
395€
Isotype Control
Human IgG4 Isotype Control antibody
PTX17887-100
180€
SIL
Stable Istotope Labelled Monalizumab Biosimilar – Anti-KLRC1/NKG2A/CD159a/CD94 mAb – Research Grade
PX-TA1392-SIL
1500€
Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Vele –
Great product!
Vele –
Great product!
Vele –
Great product!